Arsenic trioxide-based therapy is suitable for patients with psoriasis-associated acute promyelocytic leukemia - A retrospective clinical study

作者：Ge, Fei; Zhang, Yingmei; Cao, Fenglin; Li, Jinmei; Hou, Jinxiao; Wang, Ping; Li, Haitao; Xu, Mengyuan; Liu, Shuchuan; Li, Limin; Li, Xiaoxia; Wang, Shuye; Lv, Chengfang; Su, Yanhua; Zhou, Jin^*

来源：Hematology, 2016, 21(5): 287-294.

DOI：10.1080/10245332.2015.1115586

• Acute promyelocytic leukemia
• Psoriasis
• Arsenic trioxide
• Bimolane

Objective: Many patients with psoriasis have developed acute promyelocytic leukemia (APL) whereas few reports on psoriasis-associated APL were found in the published literature. This study was aimed to study the etiology, clinical characteristics, and prognosis of psoriasis-associated APL and to map a suitable treatment regime for this condition.
Methods: This study retrospectively analyzed the clinical data of 17 patients with psoriasis-associated APL diagnosed and treated in our hospital in the past decade.
Results: The 17 patients accounted for 8.3% of the total patients diagnosed with de novo APL during the same period in our hospital. Their clinical characteristics of APL were similar to those of general APL. Four patients had a definite history of taking bimolane. All patients received arsenic trioxide (ATO)-based remission induction and postremission treatment. After induction, 15 patients (88%) achieved hematologic complete remission. With a median follow-up of 27 months, the 3-year estimates of overall survival were 77.2% +/- 12.4% and the 3-year estimates of event-free survival were 70.6% +/- 13.5%. In addition, the ATO-based remission induction and postremission treatment significantly improved psoriasis symptoms in 83 and 85.7% of patients, respectively. Through the final follow-up, no chronic arsenicosis or secondary malignancy was observed.
Conclusions: Psoriasis patients are at high risk for APL. The increased risk is most likely associated with the genetic background and bimolane treatment. The ATO-based therapy is especially suitable for patients with psoriasis-associated APL. Our study also brings a new treatment option for psoriasis.

• 出版日期2016
• 单位哈尔滨医科大学